Related Experiment Video
Updated: Jun 6, 2026
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
Published on: April 15, 2022
Plasma cell labeling index correlates with deletion of 13q14 in multiple myeloma
Chunming Li1, Lijuan Chen, Xiao Gao
1Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Abstract:
Multiple myeloma (MM) is characterized by complex genetic and chromosomal abnormalities involving both numerical and structural aberrations, which have clinical prognostic value. The plasma cell labeling index (PCLI) is one of the most important prognostic factors in newly diagnosed MM, and indicates plasma cell proliferative capacity. In this study, we determined the PCLI and the deletion of 13q14, retinoblastoma-1 gene (RB-1), 1p13, and 17p13, 1q21 amplification, and IgH rearrangements in 42 newly diagnosed patients with MM. A high PCLI was observed in 18 patients (42.9%), and the del(13q14) was present in 25 patients (59.5%), del(RB-1) in 23 patients (54.8%), del(17p13) in eight patients (19.1%), amp(1q21) in 23 patients (54.7%), del(1p13) in 17 patients (40.5%), and IgH rearrangements in 28 patients (66.7%). We further detected the IgH translocation partners: t(11;14)(q13;q32), t(4;14)(p16;q32), and t(14;16)(q32;q23) in 19, 15, and five patients, respectively. The PCLI had a significant correlation with del(13q14) (p = 0.006), but no correlation with other chromosome abnormalities or clinical and laboratory features (p > 0.05). The PCLI was higher among patients with del(13q14), and patients with a high PCLI had a short time to disease progression. In conclusion, PCLI is a powerful and independent prognostic parameter in newly diagnosed MM, and correlates with del(13q14).
Insights
The plasma cell labeling index (PCLI) is a strong prognostic indicator in multiple myeloma (MM), correlating with del(13q14) and predicting disease progression. A high PCLI signifies increased plasma cell proliferation in newly diagnosed MM patients.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Multiple myeloma (MM) is a hematologic malignancy characterized by genetic abnormalities.
- Prognostic factors are crucial for managing MM, with the plasma cell labeling index (PCLI) indicating proliferative capacity.
Purpose of the Study:
- To investigate the prognostic value of PCLI in newly diagnosed MM.
- To determine the correlation between PCLI and specific chromosomal abnormalities, including del(13q14), RB-1 deletion, 1p13 deletion, 17p13 deletion, 1q21 amplification, and IgH rearrangements.
Main Methods:
- Assessed PCLI in 42 newly diagnosed MM patients.
- Utilized cytogenetic analysis to detect chromosomal abnormalities: del(13q14), RB-1, del(1p13), del(17p13), amp(1q21), and IgH rearrangements.
- Analyzed correlations between PCLI, chromosomal abnormalities, and clinical features.
Main Results:
- A high PCLI was observed in 42.9% of patients.
- del(13q14) was the most frequent abnormality (59.5%), followed by del(RB-1) (54.8%) and IgH rearrangements (66.7%).
- PCLI showed a significant positive correlation with del(13q14) (p=0.006) and was associated with a shorter time to disease progression.
Conclusions:
- PCLI is a powerful and independent prognostic marker in newly diagnosed MM.
- PCLI correlates with del(13q14), highlighting its clinical significance.
- Elevated PCLI in MM patients indicates a higher risk of rapid disease progression.
